2020

Acute Pulmonary Embolism as an Initial Presentation of Klinefelter Syndrome: A Case Report

Follow this and additional works at: https://www.j-saudi-heart.com/jsha

Part of the Cardiology Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Recommended Citation
El Ouazzani, Ghizlane; Toutai, Chaimae; Alla, Ikbal; Ismaili, Nabila; and El Ouafi, Noha (2020) "Acute Pulmonary Embolism as an Initial Presentation of Klinefelter Syndrome: A Case Report," Journal of the Saudi Heart Association: Vol. 32 : Iss. 1 , Article 21.
Available at: https://doi.org/10.37616/2212-5043.1020

This Case Report is brought to you for free and open access by Journal of the Saudi Heart Association. It has been accepted for inclusion in Journal of the Saudi Heart Association by an authorized editor of Journal of the Saudi Heart Association.
Acute pulmonary embolism as an initial presentation of Klinefelter syndrome

Ghizlane El Ouazzani*, Chaimae Toutai, Ikbal Alla, Nabila Ismaili, Noha El Ouafi

Department of Cardiology, Mohammed VI University Hospital, University Mohammed First of Oujda, 60049 Oujda, Morocco

Abstract

Venous thromboembolism (VTE) includes deep vein thrombosis and its complications and pulmonary embolism. Cancer, surgery, prolonged immobilization, fractures, paralysis, use of oral contraceptives, and hereditary coagulopathies are classic risk factors for VTE. An increased incidence of VTE has been reported in patients with Klinefelter syndrome (KS), with a reported prevalence of 0.1–0.2% in the general population and up to 3.1% in infertile men. Despite the high rate of thromboembolic disease in patients with KS, the etiology of this phenomenon is not well understood, and most of our current knowledge is limited to small sample studies. We present the case of a 56-year-old man admitted for the management of a pulmonary embolism in whom a KS was accidentally discovered.

Keywords: Klinefelter syndrome, Pulmonary embolism

1. Introduction

Klinefelter syndrome (KS) is an endocrine disorder characterized by gynecomastia, small testes, hypogonadism, and high follicle-stimulating hormone levels, usually with an XXY karyotype. The incidence of KS is approximately 1.5 per 1000 men [1]. Patients with KS appear to be at increased risk of thromboembolic events with a high prevalence of deep vein thrombosis or pulmonary embolism. Although the precise mechanisms underlying this prothrombotic state have not yet been elucidated, it is thought that the increased incidence of thromboembolism is associated with secondary hypofibrinolysis caused by androgen deficiency and the presence of chromosomal abnormalities.

2. Case report

We report the case of a 56-year-old patient with no thromboembolic risk factors, including no history of trauma, surgery, fever, weight loss, or prolonged travel. There was no family history of venous thromboembolism (VTE). He was admitted to an emergency department for the management of dyspnea New York Heart Association (NYHA) class III. Clinical examination at admission revealed a conscious patient, blood pressure at 120/80 mmHg, SpO2 at 76% in ambient air and 96% under oxygen, white lower limb edema up to mid-thigh with a positive Homans sign, and bilateral crackles on chest auscultation (Killip II).

Given the intermediate clinical probability of pulmonary embolism (Wells score at 6), a D-dimer test was requested, revealing high levels at 1832 μg/L. A chest computed tomography angiography revealed a massive pulmonary embolism in the right pulmonary artery; transthoracic echocardiography showed a dilatation of the right ventricle with a systolic dysfunction (TAPSE, 13 mm; S-wave, 8 cm/s); and the troponin level was normal at 12 ng/L (normal value, <26 ng/L). The venous Doppler ultrasound of the lower extremities revealed deep vein thrombosis of the lower left limb. For this low-risk intermediate
pulmonary embolism and deep vein thrombosis, the patient underwent anticoagulation therapy with low-molecular-weight heparin relayed by Sintron (acenocoumarol) with a target international normalized ratio between 2 and 3. The congestive signs regressed well under diuretic treatment.

During a routine physical examination, the presence of a micropenis and gynecomastia with primary sterility was discovered. Endocrine studies revealed low testosterone levels, normal prolactin levels, and high levels of follicle-stimulating hormone and luteinizing hormone. Chromosome analysis revealed a karyotype of 47,XXY (Figs. 1 and 2).

Thus, the diagnosis of KS was retained, and an endocrinological follow-up was decided as well as a blood test for thrombophilia; however, the patient refused and was eventually lost to follow-up.

3. Discussion

VTE is a common vascular disease that leads to an estimated 300,000 deaths annually [2]. Its pathogenesis is multifactorial, and its two most common clinical manifestations are pulmonary embolism and deep vein thrombosis. The classic risk factors for VTE include cancer, surgery, prolonged immobilization, fracture, paralysis, oral contraceptive use, and hereditary coagulopathies. The increased incidence of VTE was also reported in patients with KS [3–5]. The exact mechanism is not completely understood, but it is thought to be related to the inverse relationship between plasminogen activator inhibitor-1 (PAI-1) synthesis and testosterone levels [6]. High levels of PAI-1 produced by endothelial and adipose tissue inhibit tissue plasminogen activators, thereby reducing the cleavage of plasminogen to plasmin. Fibrinolytic mechanisms are significantly affected, which favors a prothrombotic state [7].

This state of hyperestrogenism may play a greater role than hypoandrogenism in the occurrence of thromboembolic disease in patients with KS, as estrogen may alter the levels of procoagulant and anticoagulant proteins, particularly in cases of coexistence of hereditary thrombophilia [8].

Nevertheless, the case reports available in the medical literature on KS and thrombosis show associated, acquired, or genetic thrombophilic

---

**Fig. 1. Chromosomal study: 47,XXY.**

---

**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>KS</td>
<td>Klinefelter syndrome</td>
</tr>
<tr>
<td>VTE</td>
<td>venous thromboembolism</td>
</tr>
</tbody>
</table>
status, particularly the antiphospholipid antibody syndrome \[3,9\]; a heterozygous state for factor V Leiden mutation 1691G>A \[10\]; compound heterozygosity for factor V Leiden 1691G>A and prothrombin 20210G>A mutations \[8,11\]; increased factor VIII coagulant activity (factor VIII: C) \[12\]; and homozygous MTHFR 1298A>C mutations \[13\].

Other hypotheses describe the pathogenesis of thromboembolism in patients with KS, namely, vascular abnormalities \[14–17\], protein C and S deficiency \[18–24\], high homocysteine levels \[13\], and antithrombin III deficiency \[14\].

It was noted that KS could also be considered to be a cause of recurrent VTE. In this case, oral anticoagulant therapy for life should be implemented in patients experiencing thromboembolic events \[15\].

4. Conclusion
KS leads to a state of hypercoagulability secondary to hyperestrogenism and hypoandrogenism, which can trigger thrombotic events in these patients, particularly in the case of a coexisting hereditary thrombotic state secondary to other chromosomal and genetic disorders. However, the mechanism behind this association is yet to be proven. Lifetime anticoagulation should therefore be recommended given the risk of recurrence of thromboembolic disease in these patients.

Conflict of interest
The authors declare no conflict of interest.

References


